Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications

Abstract

OverviewAll current antipsychotic medications work by binding to Gi-coupled dopamine (DA) D2 receptors. Such medications are thought to affect cellular function primarily by decreasing DA-mediated regulation of intracellular cyclic adenosine monophosphate (cAMP).However, several studies indicate that cAMP signal transduction abnormalities in schizophrenia may not be limited to D2-containing cells. The current study examines the potential of using non-receptor-based agents that modify intracellular signal transduction as potential antipsychotic medications. MethodsThe indirect DA agonist amphetamine has been used to model the auditory sensory processing deficits in schizophrenia. Such pharmacologically induced abnormalities are reversed by current antipsychotic treatments. This study examines the ability of the phosphodiesterase-4 inhibitor, rolipram, to reverse amphetamine-induced abnormalities in auditory-evoked potentials that are characteristic of schizophrenia. ResultsRolipram reverses amphetamine-induced reductions in auditory-evoked potentials. ConclusionThis finding could lead to novel approaches to receptor-independent treatments for schizophrenia. © 2004 IBRO. Published by Elsevier Ltd. All rights reserved.